Overview

Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This study tests the hypothesis that dapagliflozin lowers proteinuria in patients with non-diabetic chronic kidney disease.
Phase:
Phase 2
Details
Lead Sponsor:
Hiddo Lambers Heerspink
Collaborator:
AstraZeneca
Treatments:
Dapagliflozin